v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Statement of Comprehensive Income [Abstract]        
Net income before allocation to noncontrolling interests $ 3,252 $ 3,550 $ 5,710 $ 9,452
Foreign currency translation adjustments, net 194 365 1,075 (66)
Unrealized holding gains/(losses) on derivative financial instruments, net 104 (1) 189 (396)
Reclassification adjustments for (gains)/losses included in net income [1] (42) 177 (44) (242)
Other comprehensive income, cash flow hedge, gain (loss), before tax, total 62 176 145 (638)
Unrealized holding gains/(losses) on available-for-sale securities, net 6 (10) (13) 124
Reclassification adjustments for (gains)/losses included in net income [2] 19 (97) 61 (25)
Other comprehensive income (loss), available-for-sale securities, before tax, total 24 (107) 48 100
Reclassification adjustments related to amortization of prior service costs and other, net (6) (16) (20) (70)
Reclassification adjustments related to curtailments of prior service costs and other, net (2) (5) (7) (49)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax (9) (21) (26) (119)
Other comprehensive income/(loss), before tax 272 413 1,242 (723)
Tax provision/(benefit) on other comprehensive income/(loss) 23 45 156 (492)
Other comprehensive income/(loss) before allocation to noncontrolling interests 249 367 1,086 (231)
Comprehensive income/(loss) before allocation to noncontrolling interests 3,501 3,917 6,795 9,221
Less: Comprehensive income/(loss) attributable to noncontrolling interests 10 4 14 26
Comprehensive income/(loss) attributable to Pfizer Inc. $ 3,491 $ 3,913 $ 6,782 $ 9,195
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.